1. Patient Tumor Profile
TMB: 28.4 mut/Mb
2. Sequenced Somatic Neoepitopes
HLA-A*02:01 / HLA-B*07:02
Select high-affinity peptides (IC50 < 50nM) to assemble into the multi-epitope mRNA poly-neoantigen cassette.
| Include | Gene & Var | Peptide Sequence | HLA Affinity |
|---|
3. Adjuvants & Checkpoint Blockade
3 Epitopes Selected
Clinical Context:
Melanoma's high baseline ultraviolet mutational burden produces abundant neoepitopes, enabling robust polyclonality and tumor regression.
Live Tumor Microenvironment Simulation
Simulating Kinetics
Immunogenicity Score
91.4
CD8+ Expansion
14.8x
Tumor Clearance
94.2%
Exhaustion Mitigation
High (Synergized)
120-Day Clinical Response Trajectory
Day 120 / 120
Day 0
Day 120